Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab

PURPOSE: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary t...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Lalit, Thulasidas, Mithun, Purohit, Ajay, Gupta, Avnindra, Narula, Ritesh, Talwar, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Special Focus on Anti-VEGF, Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933889/
https://www.ncbi.nlm.nih.gov/pubmed/33463589
http://dx.doi.org/10.4103/ijo.IJO_2516_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933889/
https://www.ncbi.nlm.nih.gov/pubmed/33463589
http://dx.doi.org/10.4103/ijo.IJO_2516_20

Ejemplares similares